Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:CTCX NASDAQ:HYPR NASDAQ:NVNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.76-0.7%$2.72$2.15▼$22.59$20.73M-0.45214,508 shs21,314 shsCTCXCarmell$2.83-3.1%$3.01$0.17▼$1.27$59.16M0.514.65 million shs14,980 shsHYPRHyperfine$1.03-2.8%$0.81$0.53▼$1.90$82.50M1.05472,780 shs254,622 shsNVNOenVVeno Medical$4.87+5.6%$4.25$2.03▼$5.81$80.84M1139,389 shs123,359 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies+0.18%-9.06%+7.81%+21.59%-87.16%CTCXCarmell0.00%-28.08%+19.18%+1,669.70%+175.47%HYPRHyperfine-2.83%-4.63%+42.05%+49.25%-11.97%NVNOenVVeno Medical+5.64%-1.81%+23.29%+37.18%-9.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.1301 of 5 stars3.53.00.00.00.61.70.6CTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHYPRHyperfine1.0134 of 5 stars1.32.00.00.02.42.50.6NVNOenVVeno Medical0.3597 of 5 stars0.02.00.00.01.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 3.00Buy$22.83727.29% UpsideCTCXCarmell 0.00N/AN/AN/AHYPRHyperfine 2.67Moderate Buy$1.062.91% UpsideNVNOenVVeno Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALUR, NVNO, HYPR, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.68(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$32.11M0.64N/AN/A($30.08) per share-0.09CTCXCarmell$32.84K1,801.55N/AN/A$1.07 per share2.64HYPRHyperfine$12.89M6.22N/AN/A$0.67 per share1.54NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$26.15M-$12.50N/AN/AN/A-86.05%N/A-41.49%8/12/2025 (Estimated)CTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/13/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.18N/AN/AN/AN/A-54.13%-50.92%N/ALatest ALUR, NVNO, HYPR, and CTCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025HYPRHyperfine-$0.12N/AN/AN/A$3.00 millionN/A8/12/2025Q2 2025ALURAllurion Technologies-$0.65N/AN/AN/A$6.20 millionN/A7/31/2025Q2 2025NVNOenVVeno Medical-$0.28-$0.33-$0.05-$0.33N/AN/A5/14/2025Q1 2025ALURAllurion Technologies-$1.53$0.43+$1.96$0.20$5.50 million$5.58 million5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.091.88CTCXCarmellN/A0.310.29HYPRHyperfineN/A6.075.48NVNOenVVeno MedicalN/A23.7723.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%CTCXCarmell24.22%HYPRHyperfine15.03%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%CTCXCarmell29.00%HYPRHyperfine30.98%NVNOenVVeno Medical16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.46 million5.79 millionOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHYPRHyperfine19077.83 million53.72 millionOptionableNVNOenVVeno Medical3017.54 million14.73 millionOptionableALUR, NVNO, HYPR, and CTCX HeadlinesRecent News About These CompaniesenVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 1 at 8:00 AM | accessnewswire.comADauntless Investment Group LLC Purchases Shares of 70,848 enVVeno Medical Corporation (NASDAQ:NVNO)July 29, 2025 | marketbeat.comenVVeno Medical (NVNO) Projected to Post Quarterly Earnings on WednesdayJuly 29, 2025 | americanbankingnews.comenVVeno Medical (NVNO) to Release Earnings on WednesdayJuly 23, 2025 | marketbeat.comenVVeno Medical Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | indystar.comIenVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceJuly 22, 2025 | accessnewswire.comAEnVVeno Medical Reveals Promising 2-Year Data From VenoValve Clinical TrialJune 7, 2025 | nasdaq.comPositive Interim 2-Year Data from enVVeno Medical’s VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingJune 7, 2025 | cincinnati.comCPositive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingJune 6, 2025 | accessnewswire.comAEnVVeno Medical Names Jennifer Bright as CFOMay 19, 2025 | ocbj.comOenVVeno Medical Appoints Jennifer Bright as Chief Financial OfficerMay 19, 2025 | accessnewswire.comAEnVVeno has first-in-human heart valve data, expects FDA decision this yearMay 14, 2025 | massdevice.comThree-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular SurgeryMay 13, 2025 | accessnewswire.comAenVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24May 1, 2025 | accessnewswire.comAVenoValve to be Featured During Presentation at the 47th Annual Charing Cross SymposiumApril 23, 2025 | accessnewswire.comAenVVeno Medical Corp appoints CBIZ CPAs as new auditorApril 23, 2025 | investing.comenVVeno Medical to Participate in a Live Virtual Investor Closing Bell SegmentApril 16, 2025 | accessnewswire.comAAnalysis of SAVVE Pivotal Trial Data Presented for enVVeno VenoValveApril 15, 2025 | evtoday.comEThe Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual SymposiumMarch 31, 2025 | accessnewswire.comAenVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last yearMarch 1, 2025 | markets.businessinsider.comenVVeno Medical files $100M mixed securities shelfMarch 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALUR, NVNO, HYPR, and CTCX Company DescriptionsAllurion Technologies NYSE:ALUR$2.76 -0.02 (-0.72%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$2.77 +0.01 (+0.36%) As of 08/1/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Carmell NASDAQ:CTCX$2.83 -0.09 (-3.08%) As of 08/1/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Hyperfine NASDAQ:HYPR$1.03 -0.03 (-2.83%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.04 +0.01 (+1.36%) As of 08/1/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.enVVeno Medical NASDAQ:NVNO$4.87 +0.26 (+5.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.88 +0.00 (+0.10%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
